Developer docs
API playgroundTry for free, no card

Search company profiles

RxGenomix

Full company profile

uuid000sq8r

Namestring
RxGenomix
Legal namestring
RxGenomix, LLC
Websiteurl
rxgenomix.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

RxGenomix is a Tennessee-based pharmacogenomics (PGx) services company founded in 2013 that operates the ExactMeds® program and the proprietary RxGenomix Hub platform. The company's core offering is a 45-gene PGx test (analyzing drug-metabolizing enzymes such as CYP2D6, CYP2C9, CYP2C19, CYP3A4/5, VKORC1, SLCO1B1, etc.) processed via partner CLIA-certified laboratories from a cheek-swab saliva sample, combined with a clinical decision support tool that evaluates medication options against genetics, drug-drug interactions, disease state, lifestyle factors, medication cost, and Beer's list criteria. RxGenomix is positioned explicitly as a services-and-platform company rather than a laboratory, aggregating lab partners, a network of PGx-trained pharmacists, prescribers, and an online portal (hub.rxgenomix.com) that supports ordering, results access, and care coordination.

The business model is multi-stream. One-time revenue comes from individual PGx testing and from CE education courses (including an 8-hour ACPE-accredited course built with CEimpact). Professional-services revenue comes from pharmacist-led clinical consultations documented in Medication Action Plans. Recurring / enterprise revenue comes from organization-wide PGx programs sold to employers, benefits providers, and healthcare organizations, bundled with Population Analytics and practice integration services. Go-to-market combines direct enterprise sales, a pharmacist channel network, prescriber ordering via the Hub, and direct consumer ordering through the website with provider approval required to process tests. Pricing is quote-based and not publicly disclosed, with partial coverage available through some commercial insurance and Medicare for qualifying patients.

The company's strategic and operational footprint remains US-only, headcount is listed at 1-10, and it discloses no institutional funding rounds. Anchor enterprise relationships include a partnership with prescription benefit facilitator BeneCardPBF (announced December 2019) and an integration with precision-medicine technology provider Translational Software (May 2020). Leadership includes CEO Brad Tice (PharmD, MBA), COO Blake Keller (PharmD), SVP of IT Brad Mitchell, and Director of Clinical Pharmacogenomic Operations Dr. Ina Liko (PharmD, MSCS). The company is HIPAA-verified, recognized as a 2023 NEXT Award winner in Middle Tennessee, and its reporting structure flags that genetic health risk information is not FDA-reviewed — consistent with a regulated but non-device clinical service.

Short descriptiontext

RxGenomix is a Tennessee-based pharmacogenomics services company that analyzes 45 drug-metabolism genes and operates the ExactMeds program and RxGenomix Hub platform to deliver personalized prescribing for individuals, employers, benefit providers, pharmacists, and prescribers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFranklin, United States
HQ citystring
Franklin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmacogenomics testing, personalized medication management, clinical decision support, pharmacy consultation services, genetic drug response
Industry3 codes
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmacogenomics Services
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1PGx Testing Services
TypeOne Time License
Description

One-time pharmacogenomic testing for individuals, ordered by healthcare providers. Saliva sample collected via cheek swab, processed by partner CLIA-certified laboratories. Test results stored for future reference.

rxgenomix.com
2Clinical Consultation Services
TypeProfessional Services
Description

PGx-trained pharmacists provide consultation services to healthcare providers based on test results. Pharmacists earn reimbursement for consultations and can add this as a revenue-generating service line to their practice.

rxgenomix.com
3Enterprise/Benefit Program Solutions
TypeSubscription Recurring
Description

Population-level PGx programs sold to employers, benefit providers, and healthcare organizations. Includes analytics, testing coordination, pharmacist network access, and ongoing program management.

rxgenomix.com
4CE Education Courses
TypeOne Time License
Description

Continuing education courses for pharmacists and healthcare providers on pharmacogenomics, including an 8-hour accredited course and free introductory courses.

rxgenomix.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 record
1ExactMeds
Description

The pharmacogenomic testing program and brand offering personalized medication therapy based on individual genetics.

rxgenomix.com
Core offering1 text field

RxGenomix operates a pharmacogenomics (PGx) services platform that combines a 45-gene genetic test (cheek swab, processed at partner CLIA-certified labs) with the proprietary RxGenomix Hub — a secure portal providing clinical decision support, population analytics, and pharmacist-led consultations. The company sells ExactMeds® testing programs to individuals (via provider order), to employers and benefit providers (enterprise solutions), and to pharmacists (practice integration), supported by an ACPE-accredited CE training course.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 29% reduction in hospitalizations and 18% reduction in pharmacy expenses for retiree groups implementing ExactMeds program
+4 more records
Product overview1 text field

RxGenomix is a pharmacogenomics (PGx) services company offering ExactMeds®, a comprehensive and highly scalable approach to personalized medicine. The portfolio includes: the RxGenomix Hub platform (connecting care teams and providing clinical decision support), Individual Testing services (cheek swab-based testing of 45 genes), Enterprise Solutions and Population Analytics (for employers and benefit providers), and Practice Integration services (for pharmacists). The ecosystem is supported by educational offerings including an 8-hour ACPE-accredited CE course and monthly Clinical Pearls webinars. All offerings center on using genetic testing to guide personalized prescribing decisions.

Product and service4 records
1ExactMeds®
CategoryPharmacogenomics Testing Program
Description

Primary pharmacogenomic testing program and brand that analyzes patient genetics to guide personalized medication selection and dosing, intended to reduce adverse drug events and improve treatment outcomes for individuals, healthcare providers, benefit administrators, and employers.

2RxGenomix Hub
CategoryClinical Platform / Software
Description

Proprietary, secure online portal connecting pharmacists, physicians, nurse practitioners and patients to order tests, access results, deliver clinical decision support, and coordinate personalized medication care.

3Individual Testing
CategoryPGx Testing Service
Description

Pharmacogenomic testing for individual patients using a cheek swab DNA sample analyzed for 45 genes affecting drug metabolism, with results interpreted by PGx-trained pharmacists and shared with the patient's prescribing provider.

4Enterprise Solutions
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Base Camp Health
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-06-17
Description

Partnership for innovative return-to-work solution combining PGx testing with digital daily monitoring. RxGenomix added Base Camp Health's digital monitoring solution to offer comprehensive COVID-19 workplace response capabilities.

rxgenomix.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-05-12
Description

Partnership with Translational Software (TSI), a leader in intelligent use of genetic data for clinical decision support and precision medicine. The partnership increases the value of individual offerings and makes pharmacogenomic services more comprehensive by combining RxGenomix's testing and pharmacist network with TSI's clinical decision support technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-12-17
Description

Innovative prescription benefit facilitator that leverages the RxGenomix Hub to deliver personalized medication care for their members. BeneCardPBF strives to bring the best solutions to clients and members, and the RxGenomix integration is part of their leadership in the industry.

Strategic tierCoreTypeTechnology or Integration
Description

RxGenomix partners with clinical testing laboratories accredited by the College of American Pathologists and certified under Clinical Laboratory Improvement Amendments (CLIA) for high complexity testing. These partnerships enable the actual genetic testing processing for the PGx panel.

5CEimpact
Strategic tierCoreTypeStrategic or Co-development Partner
Description

RxGenomix provided support to CEimpact to create the 8-hour ACPE-accredited Pharmacogenomics: A Training for Pharmacists continuing education course. This partnership enables pharmacist training and credentialing for the RxGenomix network.

rxgenomix.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RxGenomix

Pharmacogenomics Servicesrxgenomix.com

RxGenomix is a Tennessee-based pharmacogenomics services company that analyzes 45 drug-metabolism genes and operates the ExactMeds program and RxGenomix Hub platform to deliver personalized prescribing for individuals, employers, benefit providers, pharmacists, and prescribers.

What RxGenomix does

RxGenomix is a Tennessee-based pharmacogenomics (PGx) services company founded in 2013 that operates the ExactMeds® program and the proprietary RxGenomix Hub platform. The company's core offering is a 45-gene PGx test (analyzing drug-metabolizing enzymes such as CYP2D6, CYP2C9, CYP2C19, CYP3A4/5, VKORC1, SLCO1B1, etc.) processed via partner CLIA-certified laboratories from a cheek-swab saliva sample, combined with a clinical decision support tool that evaluates medication options against genetics, drug-drug interactions, disease state, lifestyle factors, medication cost, and Beer's list criteria. RxGenomix is positioned explicitly as a services-and-platform company rather than a laboratory, aggregating lab partners, a network of PGx-trained pharmacists, prescribers, and an online portal (hub.rxgenomix.com) that supports ordering, results access, and care coordination.

The business model is multi-stream. One-time revenue comes from individual PGx testing and from CE education courses (including an 8-hour ACPE-accredited course built with CEimpact). Professional-services revenue comes from pharmacist-led clinical consultations documented in Medication Action Plans. Recurring / enterprise revenue comes from organization-wide PGx programs sold to employers, benefits providers, and healthcare organizations, bundled with Population Analytics and practice integration services. Go-to-market combines direct enterprise sales, a pharmacist channel network, prescriber ordering via the Hub, and direct consumer ordering through the website with provider approval required to process tests. Pricing is quote-based and not publicly disclosed, with partial coverage available through some commercial insurance and Medicare for qualifying patients.

The company's strategic and operational footprint remains US-only, headcount is listed at 1-10, and it discloses no institutional funding rounds. Anchor enterprise relationships include a partnership with prescription benefit facilitator BeneCardPBF (announced December 2019) and an integration with precision-medicine technology provider Translational Software (May 2020). Leadership includes CEO Brad Tice (PharmD, MBA), COO Blake Keller (PharmD), SVP of IT Brad Mitchell, and Director of Clinical Pharmacogenomic Operations Dr. Ina Liko (PharmD, MSCS). The company is HIPAA-verified, recognized as a 2023 NEXT Award winner in Middle Tennessee, and its reporting structure flags that genetic health risk information is not FDA-reviewed — consistent with a regulated but non-device clinical service.

RxGenomix firmographics

Firmographics
Name
RxGenomix
Legal name
RxGenomix, LLC
Website
https://rxgenomix.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
RxGenomix is a Tennessee-based pharmacogenomics services company that analyzes 45 drug-metabolism genes and operates the ExactMeds program and RxGenomix Hub platform to deliver personalized prescribing for individuals, employers, benefit providers, pharmacists, and prescribers.
Ownership category
akta.pro rank

RxGenomix industry classification

Industry
Product category
Pharmacogenomics Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics

Keywords

  • Pharmacogenomics testing
  • Personalized medication management
  • Clinical decision support
  • Pharmacy consultation services
  • Genetic drug response

Where RxGenomix is headquartered

Location

Headquarters

HQ city
Franklin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

RxGenomix business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. PGx Testing Services: One-time pharmacogenomic testing for individuals, ordered by healthcare providers. Saliva sample collected via cheek swab, processed by partner CLIA-certified laboratories. Test results stored for future reference.
  2. Clinical Consultation Services: PGx-trained pharmacists provide consultation services to healthcare providers based on test results. Pharmacists earn reimbursement for consultations and can add this as a revenue-generating service line to their practice.
  3. Enterprise/Benefit Program Solutions: Population-level PGx programs sold to employers, benefit providers, and healthcare organizations. Includes analytics, testing coordination, pharmacist network access, and ongoing program management.
  4. CE Education Courses: Continuing education courses for pharmacists and healthcare providers on pharmacogenomics, including an 8-hour accredited course and free introductory courses.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

RxGenomix product offering

Product offering

Core offering

RxGenomix operates a pharmacogenomics (PGx) services platform that combines a 45-gene genetic test (cheek swab, processed at partner CLIA-certified labs) with the proprietary RxGenomix Hub — a secure portal providing clinical decision support, population analytics, and pharmacist-led consultations. The company sells ExactMeds® testing programs to individuals (via provider order), to employers and benefit providers (enterprise solutions), and to pharmacists (practice integration), supported by an ACPE-accredited CE training course.

Product overview

RxGenomix is a pharmacogenomics (PGx) services company offering ExactMeds®, a comprehensive and highly scalable approach to personalized medicine. The portfolio includes: the RxGenomix Hub platform (connecting care teams and providing clinical decision support), Individual Testing services (cheek swab-based testing of 45 genes), Enterprise Solutions and Population Analytics (for employers and benefit providers), and Practice Integration services (for pharmacists). The ecosystem is supported by educational offerings including an 8-hour ACPE-accredited CE course and monthly Clinical Pearls webinars. All offerings center on using genetic testing to guide personalized prescribing decisions.

Differentiator

Problem solved

Functional benefit

Brands

  • ExactMeds: The pharmacogenomic testing program and brand offering personalized medication therapy based on individual genetics.

Products and services

  • ExactMeds® Primary pharmacogenomic testing program and brand that analyzes patient genetics to guide personalized medication selection and dosing, intended to reduce adverse drug events and improve treatment outcomes for individuals, healthcare providers, benefit administrators, and employers.
  • RxGenomix Hub Proprietary, secure online portal connecting pharmacists, physicians, nurse practitioners and patients to order tests, access results, deliver clinical decision support, and coordinate personalized medication care.
  • Individual Testing Pharmacogenomic testing for individual patients using a cheek swab DNA sample analyzed for 45 genes affecting drug metabolism, with results interpreted by PGx-trained pharmacists and shared with the patient's prescribing provider.
  • Enterprise Solutions

Quantifiable outcome

  • 29% reduction in hospitalizations and 18% reduction in pharmacy expenses for retiree groups implementing ExactMeds program
  • +4 more outcomes

Companies that use RxGenomix

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

RxGenomix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

RxGenomix partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Base Camp HealthminorStrategic or Co-development Partner · 17 June 2020Partnership for innovative return-to-work solution combining PGx testing with digital daily monitoring. RxGenomix added Base Camp Health's digital monitoring solution to offer comprehensive COVID-19 workplace response capabilities.
  • Translational SoftwarecoreTechnology or Integration · 12 May 2020Partnership with Translational Software (TSI), a leader in intelligent use of genetic data for clinical decision support and precision medicine. The partnership increases the value of individual offerings and makes pharmacogenomic services more comprehensive by combining RxGenomix's testing and pharmacist network with TSI's clinical decision support technology.
  • BeneCardPBFcoreStrategic or Co-development Partner · 17 December 2019Innovative prescription benefit facilitator that leverages the RxGenomix Hub to deliver personalized medication care for their members. BeneCardPBF strives to bring the best solutions to clients and members, and the RxGenomix integration is part of their leadership in the industry.
  • CLIA-certified Laboratory PartnerscoreTechnology or IntegrationRxGenomix partners with clinical testing laboratories accredited by the College of American Pathologists and certified under Clinical Laboratory Improvement Amendments (CLIA) for high complexity testing. These partnerships enable the actual genetic testing processing for the PGx panel.
  • CEimpactcoreStrategic or Co-development PartnerRxGenomix provided support to CEimpact to create the 8-hour ACPE-accredited Pharmacogenomics: A Training for Pharmacists continuing education course. This partnership enables pharmacist training and credentialing for the RxGenomix network.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

RxGenomix competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

RxGenomix social profiles

Digital presence

RxGenomix compliance and trust

Trust signal

Compliance2 records

RxGenomix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RxGenomix leadership team

Management profile

Number of profiles

Profiles4 records

RxGenomix funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RxGenomix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RxGenomix

What does RxGenomix do?

RxGenomix operates a pharmacogenomics (PGx) services platform that combines a 45-gene genetic test (cheek swab, processed at partner CLIA-certified labs) with the proprietary RxGenomix Hub — a secure portal providing clinical decision support, population analytics, and pharmacist-led consultations. The company sells ExactMeds® testing programs to individuals (via provider order), to employers and benefit providers (enterprise solutions), and to pharmacists (practice integration), supported by an ACPE-accredited CE training course.

Is RxGenomix a public or private company?

RxGenomix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was RxGenomix founded?

RxGenomix was founded in 2013. It employs 11 to 50 people.

Where is RxGenomix based?

RxGenomix is headquartered in Franklin, United States, in the North America region.

How does RxGenomix make money?

Four revenue lines are on record. PGx Testing Services are the primary driver. The others are clinical Consultation Services, enterprise/Benefit Program Solutions and CE Education Courses.

Does RxGenomix have an API?

No public API is recorded for RxGenomix.

What industry is RxGenomix in?

RxGenomix's product category is Pharmacogenomics Services. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireData Facts Announces Partnership with RxGenomix for COVID-19 Employee TestingData Facts announced a partnership with RxGenomix to provide employers with COVID-19 screening and testing tools, including digital screening, temperature monitoring, and diagnostic/antibody testing. The partnership aims to help companies return to work safely by offering cost-effective, easy-to-implement solutions.PR NewswireRxGenomix and Translational Software Announce PartnershipRxGenomix and Translational Software have announced a strategic partnership to combine their pharmacogenomics solutions, aiming to improve clinical outcomes and reduce healthcare costs. The collaboration integrates RxGenomix's claims analytics and pharmacist-led programs with Translational Software's clinical decision support tools to make genetic testing more accessible to employers, payors, and providers.PR NewswireInnovative Pharmacogenetics Hub Delivers New Level Of Personalized Care For PatientsBeneCard PBF, a pharmacist-founded prescription benefit manager, has partnered with RxGenomix to offer pharmacogenetic testing through a new digital coordination platform called the RxGenomix Hub, making it one of the first PBMs to provide this service. The platform enables real-time coordination between patients' entire care teams—including primary care providers, specialists, pharmacists, and PBM clinicians—to personalize medication therapy based on genetic profiles. The companies claim this approach can eliminate inefficient trial-and-error prescribing, improve patient outcomes, and generate cost savings for patients and plan sponsors.PR NewswireRxGenomix and Coriell Life Sciences Announce PartnershipRxGenomix and Coriell Life Sciences announced a partnership to combine their pharmacogenomics solutions, integrating RxGenomix's pharmacist-led training program with CLS's risk analysis and population-level analytics. The combined offering aims to make pharmacogenomic testing more accessible and effective in improving patient care while reducing overall healthcare costs. Adverse drug reactions kill more than 120,000 people annually in the U.S., underscoring the clinical need this partnership seeks to address.PR NewswireBlake Keller, PharmD, Joins RxGenomix In Key Leadership RoleBlake Keller, PharmD has been appointed Chief Operating Officer at RxGenomix, a Nashville-based pharmacogenomics solutions company. Keller, an 18-year healthcare industry veteran, previously served as President, North America of Fagron and Vice President of Premise Health. His role will focus on product diversification, service delivery strategy, and accelerating the company's infrastructure and revenue generation channels in anticipation of significant growth in 2019.